The role of CD4+ T helper cells in the cytotoxic T lymphocyte response to HIV-1

Current Opinion in Immunology

Volumn 12, Issue 4, 2000, Pages 375-380

  Altfeld, Marcus ^a   Rosenberg, Eric S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

CELLULAR IMMUNITY; CHRONIC DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; REVIEW;

EID: 0034123842     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00103-5     Document Type: Review

References (60)

1. Brander C., Walker B.D. T lymphocyte responses in HIV-1 infection: implications for vaccine development. Curr Opin Immunol. 11:1999;451-459.
2. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 68:1994;8056-8063.
3. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., Walker B.D. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
4. Kalams S.A., Buchbinder S.P., Rosenberg E.S., Billingsley J.M., Colbert D.S., Jones N.G., Shea A.K., Trocha A.K., Walker B.D. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol. 73:1999;6715-6720. This paper shows, for the first time, a strong association between Gag-specific CTL responses and p24-specific T helper cell responses.
5. von Herrath M.G., Yokoyama M., Dockter J., Oldstone M.B., Whitton J.L. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol. 70:1996;1072-1079.
6. Ahmed R., Butler L.D., Bhatti L. T4+ T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses. J Virol. 62:1988;2102-2106.
7. Battegay M., Moskophidis D., Rahemtulla A., Hengartner H., Mak T.W., Zinkernagel R.M. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol. 68:1994;4700-4704.
8. Cardin R.D., Brooks J.W., Sarawar S.R., Doherty P.C. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med. 184:1996;863-871.
9. Manickan E., Rouse B.T. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models. J Virol. 69:1995;8178-8179.
10. Hasenkrug K.J., Brooks D.M., Dittmer U. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol. 72:1998;6559-6564.
11. Stohlman S.A., Bergmann C.C., Lin M.T., Cua D.J., Hinton D.R. CTL effector function within the central nervous system requires CD4+ T cells. J Immunol. 160:1998;2896-2904.
12. Mortara L., Gras-Masse H., Rommens C., Venet A., Guillet J.G., Bourgault-Villada I. Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol. 73:1999;4447-4451.
13. Shirai M., Pendleton C.D., Ahlers J., Takeshita T., Newman M., Berzofsky J.A. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol. 152:1994;549-556.
14. Partidos C.D., Delmas A., Steward M.W. Structural requirements for synthetic immunogens to induce measles virus specific CTL responses. Mol Immunol. 33:1996;1223-1229.
15. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
16. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 188:1998;2205-2213.
17. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 78:1991;1373-1380.
18. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 333:1995;1038-1044.
19. Komanduri K.V., Viswanathan M.N., Wieder E.D., Schmidt D.K., Bredt B.M., Jacobson M.A., McCune J.M. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 4:1998;953-956.
20. Li T.S., Tubiana R., Fillet A.M., Autran B., Katlama C. Negative result of cytomegalovirus blood culture with restoration of CD4+ T-cell reactivity to cytomegalovirus after HAART in an HIV-1- infected patient. J Acquir Immune Defic Syndr Hum Retrovirol. 20:1999;514-515.
21. Koziel M.J. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat. 4:1997;31-41.
22. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1995;1006-1007.
23. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 98:1996;706-714.
24. + T helper cell responses are essential for eliminating virus during the acute phase of disease and must be permanently maintained to achieve long-term viral control.
25. Eyster M.E., Fried M.W., Di Bisceglie A.M., Goedert J.J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 84:1994;1020-1023.
26. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V.et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
27. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 68:1994;6103-6110.
28. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 68:1994;4650-4655.
29. Yang O.O., Walker B.D. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv Immunol. 66:1997;273-311.
30. •].
31. + T cells.
32. Lane H.C., Depper J.M., Greene W.C., Whalen G., Waldmann T.A., Fauci A.S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 313:1985;79-84.
33. Murray H.W., Rubin B.Y., Masur H., Roberts R.B. Impaired production of lymphokines and immune (gamma) interferon in the acquired immuno-deficiency syndrome. N Engl J Med. 310:1984;883-889.
34. Musey L.K., Krieger J.N., Hughes J.P., Schacker T.W., Corey L., McElrath M.J. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 180:1999;278-284.
35. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 57:1993;183-289.
36. Groux H., Torpier G., Monte D., Mouton Y., Capron A., Ameisen J.C. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med. 175:1992;331-340.
37. Cottrez F., Manca F., Dalgleish A.G., Arenzana-Seisdedos F., Capron A., Groux H. Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. J Clin Invest. 99:1997;257-266.
38. Wahren B., Morfeldt-Mansson L., Biberfeld G., Moberg L., Sonnerborg A., Ljungman P., Werner A., Kurth R., Gallo R., Bolognesi D. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol. 61:1987;2017-2023.
39. Berzofsky J.A., Bensussan A., Cease K.B., Bourge J.F., Cheynier R., Lurhuma Z., Salaun J.J., Gallo R.C., Shearer G.M., Zagury D. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature. 334:1988;706-708.
40. Krowka J.F., Stites D.P., Jain S., Steimer K.S., George-Nascimento C., Gyenes A., Barr P.J., Hollander H., Moss A.R., Homsy J.M. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest. 83:1989;1198-1203.
41. Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M.et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 69:1995;5838-5842.
42. Klein M.R., van Baalen C.A., Holwerda A.M., Kerkhof-Garde S.R., Bende R.J., Keet I.P., Eeftinck-Schattenkerk J.K., Osterhaus A.D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 181:1995;1365-1372.
43. + T cells. However, the ability of these CTLs to produce IFN-γ in response to specific stimulation was impaired.
44. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., Cao Y., Ho D.D., Yilma T., Caliendo A.M.et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retrovirus. 12:1996;585-592.
45. Harrer T., Harrer E., Kalams S.A., Barbosa P., Trocha A., Johnson R.P., Elbeik T., Feinberg M.B., Buchbinder S.P., Walker B.D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 156:1996;2616-2623.
46. Schwartz D., Sharma U., Busch M., Weinhold K., Matthews T., Lieberman J., Birx D., Farzedagen H., Margolick J., Quinn T.et al. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retrovirus. 10:1994;1703-1711.
47. Wasik T.J., Wierzbicki A., Whiteman V.E., Trinchieri G., Lischner H.W., Kozbor D. Association between HIV-specific T helper responses and CTL activities in pediatric AIDS. Eur J Immunol. 30:2000;117-127.
48. Pitcher C.J., Quittner C., Peterson D.M., Connors M., Koup R.A., Maino V.C., Picker L.J. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 5:1999;518-525. This is the first description of intracellular IFN-γ production in cells stimulated with p55 and p24 in persons with chronic HIV-1 infection. The responses were strongest in long-term nonprogressors and declined in treated individuals.
49. Kalams S.A., Goulder P.J., Shea A.K., Jones N.G., Trocha A.K., Ogg G.S., Walker B.D. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol. 73:1999;6721-6728.
50. Ogg G.S., Jin X., Bonhoeffer S., Moss P., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Hurley A.et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 73:1999;797-800.
51. + T helper cell responses to different antigens in greater detail.
52. McMichael A.J., Kelleher A. The arrival of HLA class II tetramers. J Clin Invest. 104:1999;1669-1670.
53. Rosenberg E.S., Walker B.D. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retrovirus. 14(suppl 2):1998;143-147.
54. Malhotra U., Berrey M.M., Huang Y., Markee J., Brown D.J., Ap S., Musey L., Schacker T., Corey L., McElrath M.J. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 181:2000;121-131.
55. Dalod M., Dupuis M., Deschemin J.C., Goujard C., Deveau C., Meyer L., Ngo N., Rouzioux C., Guillet J.G., Delfraissy J.F.et al. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest. 104:1999;1431-1439.
56. Dalod M., Harzic M., Pellegrin I., Dumon B., Hoen B., Sereni D., Deschemin J.C., Levy J.P., Venet A., Gomard E. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis. 178:1998;61-69.
57. Pantaleo G., Soudeyns H., Demarest J.F., Vaccarezza M., Graziosi C., Paolucci S., Daucher M., Cohen O.J., Denis F., Biddison W.E.et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA. 94:1997;9848-9853.
58. •].
59. •] describe HIV-1-infected individuals who were treated early after primary infection and who interrupted antiretroviral treatment. Re-exposure to HIV-1 during treatment interruption increased virus-specific cellular immune responses in these individuals and was associated in some individuals with spontaneous control of HIV-1 viremia without any treatment. These reports are interesting but are limited by the small number of subjects and retrospective analysis of data.
60. Goulder P.J.R. Treat acute HIV at an early stage. HIV & AIDS Current Trends. 5:1999;6-8.